Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy

Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression

(2022) Guillaume Dorcet et al.   JOURNAL OF NEUROLOGY

Proinflammatory CD20 + T cells contribute to CNS-directed autoimmunity

(2022) Jasmin Ochs et al.   Science Translational Medicine

Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab

(2022) Doriana Landi et al.   Neurology-Neuroimmunology & Neuroinflammation

Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders

(2022) Su-Hyun Kim et al.   Neurology-Neuroimmunology & Neuroinflammation

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

(2022) Lawrence Steinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Updated Results of the COVID-19 in MS Global Data Sharing Initiative

(2022) Steve Simpson-Yap et al.   Neurology-Neuroimmunology & Neuroinflammation

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis

(2022) Chiara Starvaggi Cucuzza et al.   Neurology-Neuroimmunology & Neuroinflammation

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis

(2021) Malin Boremalm et al.   JOURNAL OF NEUROLOGY

Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study

(2021) Nabil Seery et al.   CNS DRUGS

Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis

(2021) Caroline Ruetsch-Chelli et al.   Neurotherapeutics

Proinflammatory CD20 + T cells are differentially affected by MS therapeutics

(2021) Corinna Quendt et al.   ANNALS OF NEUROLOGY

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

(2021) Bianca Weinstock-Guttman et al.   Multiple Sclerosis Journal

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic

(2021) Zoë YGJ van Lierop et al.   Multiple Sclerosis Journal

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis

(2021) Maria Cellerino et al.   Neurotherapeutics

Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases

(2021) N.R. Oksbjerg et al.   Multiple Sclerosis and Related Disorders

Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis

(2021) Krista D. DiSano et al.   Frontiers in Immunology

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

(2021) Leoni Rolfes et al.   Neurology-Neuroimmunology & Neuroinflammation

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study

(2021) Amit Bar-Or et al.   Multiple Sclerosis Journal

Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab

(2021) Marine Perriguey et al.   Neurology-Neuroimmunology & Neuroinflammation

Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis

(2020) Luca Prosperini et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity

(2020) Erin E Longbrake et al.   Multiple Sclerosis Journal

Ofatumumab versus Teriflunomide in Multiple Sclerosis

(2020) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serious safety events in rituximab‐treated multiple sclerosis and related disorders

(2020) Brandi L. Vollmer et al.   Annals of Clinical and Translational Neurology

Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?

(2020) Adil Maarouf et al.   Neurology-Neuroimmunology & Neuroinflammation

Tailoring B cell depletion therapy in MS according to memory B cell monitoring

(2020) Giovanni Novi et al.   Neurology-Neuroimmunology & Neuroinflammation

B cells reappear less mature and more activated after their anti-CD20–mediated depletion in multiple sclerosis

(2020) Nitzan Nissimov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

(2020) David Baker et al.   Multiple Sclerosis and Related Disorders

Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

(2019) Chiara Zecca et al.   Multiple Sclerosis Journal

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

(2019) Gustavo Luna et al.   JAMA Neurology

Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study

(2018) Carmen Alcalá et al.   JOURNAL OF NEUROLOGY

Efficacy of rituximab in refractory RRMS

(2018) Pierre Durozard et al.   Multiple Sclerosis Journal

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis

(2018) Amit Bar-Or et al.   NEUROLOGY

Efficacy of rituximab in refractory RRMS

(2018) Pierre Durozard et al.   Multiple Sclerosis Journal

Unraveling treatment response in multiple sclerosis

(2018) Claudio Gasperini et al.   NEUROLOGY

Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: A systematic review and meta-analysis

(2018) Gonçalo Boleto et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis

(2016) Christine Lebrun et al.   JOURNAL OF NEUROIMMUNOLOGY

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease

(2015) Darren M. Roberts et al.   JOURNAL OF AUTOIMMUNITY

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

(2015) R. F. van Vollenhoven et al.   JOURNAL OF RHEUMATOLOGY

Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients

(2014) Arumugam Palanichamy et al.   JOURNAL OF IMMUNOLOGY

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF

(2014) Clemens Warnke et al.   Multiple Sclerosis Journal

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort

(2013) O. Outteryck et al.   EUROPEAN JOURNAL OF NEUROLOGY

A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder

(2013) Su-Hyun Kim et al.   JAMA Neurology

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE